Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2012-08-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2012年第二次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, procedures, and resolutions of the 2012 second extraordinary shareholders' meeting of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the legality and validity of the meeting's call, attendance, agenda, voting procedures, and results. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a legal opinion related to a shareholders' meeting, specifically focusing on the validation of the meeting and its resolutions. This type of document is best classified under Regulatory Filings (RNS) as it is a legal compliance document and does not fit into other specific categories such as AGM Information or Declaration of Voting Results, which would typically be the actual meeting materials or voting results announcements. The document length is short (2587 characters), and it is not an announcement of a report but the legal opinion itself.
2012-08-17 Chinese
关于第二大股东新乡白鹭化纤集团有限公司股权解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a short announcement regarding the release of pledged shares by a major shareholder. It details the number of shares released from pledge and the updated pledge status. There is no financial data, no report attached or referenced as being published, and no mention of management changes or voting results. This fits the category of a Major Shareholding Notification, as it informs about changes in significant share ownership or related shareholding status.
2012-08-04 Chinese
独立董事对公司累计和当期对外担保及关联方资金占用情况的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the company's external guarantees and related party fund occupation as of June 30, 2012. It references regulatory notices from the China Securities Regulatory Commission and confirms compliance with disclosure and approval procedures. The document is a formal statement or certification by independent directors rather than a full audit report or annual report. It does not contain detailed financial statements or comprehensive audit results but rather an attestation about specific compliance matters. Given its nature as an independent opinion letter related to regulatory compliance and internal controls, it fits best under Audit Report / Information (AR) rather than a full Annual Report or Regulatory Filing. The document length is short and focused on audit-related opinions, not a general regulatory filing or announcement of a report publication. H1 2012
2012-07-20 Chinese
第五届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the approval of the 2012 semi-annual report and its summary, as well as amendments to the company's articles of association. The document states that the Supervisory Board has reviewed and approved the 2012 semi-annual report and summary, but the full report is available on the designated information disclosure website and is not included in this document. The document is short (928 characters) and serves as an announcement of the approval and related resolutions rather than the report itself. Therefore, it fits the category of Regulatory Filings (RNS) as it is a formal announcement related to corporate governance and report approval but does not contain the full financial report or detailed financial data itself.
2012-07-20 Chinese
第五届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's fifth board meeting, including approval of the 2012 semi-annual report and amendments to the company's articles of association related to profit distribution policies. It also announces the scheduling of a shareholders' meeting. The document does not contain the full semi-annual report itself but references where it can be found. The main content is about board decisions and corporate governance changes, specifically amendments to the company charter and profit distribution rules. This fits the category of Board/Management Information (MANG), as it announces board meeting resolutions and governance changes. The document length is short (3126 characters), and it is not the full financial report but an announcement of board decisions and related governance matters.
2012-07-20 Chinese
2012年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "北京双鹭药业股份有限公司 2012 年半年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2012 Semi-Annual Report Full Text." It contains detailed financial data for the first half of 2012, including income, profit, assets, equity, earnings per share, and cash flow. It also includes sections on company basic information, shareholding structure, board and management details, and other comprehensive disclosures typical of a semi-annual financial report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of unaudited financial statements and detailed management and shareholder information confirms it is an Interim / Quarterly Report. Therefore, the appropriate classification is "Interim / Quarterly Report (IR)" with high confidence. H1 2012
2012-07-20 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.